A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions
PHASE1CompletedINTERVENTIONAL
Enrollment
16
Participants
Timeline
Start Date
March 17, 2025
Primary Completion Date
April 21, 2025
Study Completion Date
April 21, 2025
Conditions
Lassa Virus Infection
Interventions
DRUG
ARN-75039
An oral therapy for the treatment of Lassa infection
NCT06911242 - A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions | Biotech Hunter | Biotech Hunter